Prognosis for a patient with high-grade ovarian carcinoma (FIGO stage IIIc) who has undergone surgery with no macroscopic residual tumour and received standard therapy with paclitaxel, carboplatin, and bevacizumab:
Achieving complete macroscopic cytoreduction (no visible residual tumour) is the strongest prognostic factor for improved progression-free survival (PFS) and overall survival (OS) in advanced high-grade ovarian carcinoma, including FIGO stage IIIc disease NICE CG122,NICE,Runnebaum et al. 2026.
Standard adjuvant chemotherapy for such patients consists of carboplatin and paclitaxel for six cycles, to which bevacizumab can be added as part of first-line therapy, especially in patients with high-risk disease such as stage III with residual tumour or stage IV SmPC Abevmy,SmPC Avastin,NICE.
The addition of bevacizumab to carboplatin and paclitaxel significantly improves median PFS from approximately 16.9 months to 19.3 months, with a hazard ratio of 0.86 favoring the combination, reflecting a statistically significant benefit (p=0.0185) SmPC Abevmy,SmPC Avastin. However, bevacizumab does not significantly impact median overall survival, which remains around 58 months SmPC Abevmy,SmPC Avastin.
In terms of long-term outcomes, a complete macroscopic resection followed by chemotherapy plus bevacizumab aligns with current best practice and provides a progression-free survival benefit, though overall survival improvement is less clear per trial data SmPC Abevmy,SmPC Avastin,NICE.
Recent literature from a large European cohort Runnebaum et al. 2026 supports the prognostic benefit of complete cytoreduction in FIGO stage IIIC–IV ovarian cancer and notes that while surgical complexity and certain bowel resections may increase morbidity, the absence of macroscopic residual disease is associated with improved survival outcomes.
However, small bowel and ileocecal resections—markers of more extensive disease involvement—are independently associated with poorer progression-free and overall survival, even if macroscopic complete resection is achieved Runnebaum et al. 2026. This indicates that extent and sites of disease spread beyond residual tumour size impact prognosis.
The median progression-free survival in advanced ovarian cancer treated with carboplatin, paclitaxel, and bevacizumab is approximately 19.3 months, while overall survival is around 58 months SmPC Abevmy,SmPC Avastin, but individual prognosis may vary based on disease distribution and patient factors.
Therefore, for a patient with high-grade ovarian carcinoma FIGO stage IIIc who has undergone optimal cytoreductive surgery with no residual tumour and received standard chemotherapy with paclitaxel, carboplatin, and bevacizumab, the prognosis is relatively favourable compared to patients with residual disease, with median PFS near 19 months and median OS near 58 months, although progression and survival can be influenced by disease burden and other clinical factors SmPC Abevmy,SmPC Avastin,NICE,Runnebaum et al. 2026.
Key References
- SmPC: Abevmy 25 mg/mL concentrate for solution for infusion
- SmPC: Avastin 25mg/ml concentrate for solution for infusion
- SmPC: Alymsys 25 mg/mL concentrate for solution for infusion
- NICE CG122: Ovarian cancer: recognition and initial management
- NICE CKS: HPV and cervical cancer
- NICE CKS: Ovarian cancer
- NICE NG101: Early and locally advanced breast cancer: diagnosis and management
- (Runnebaum et al., 2026): Ileocecal and Small Bowel Involvement Are Independently Associated with Inferior Survival Despite Complete Cytoreduction in FIGO IIIC-IV Tubo-Ovarian and Primary Peritoneal Carcinoma.
- (Zuo et al., 2025): Case Report: A rare case of hepatoid carcinoma of the ovary with genomic profiling and long-term follow-up: diagnostic and therapeutic perspectives.
- (Arcieri et al., 2025): Management of Patients with Epithelial Ovarian Cancer: A Systematic Comparison of International Guidelines from Scientific Societies (AIOM-BGCS-ESGO-ESMO-JGSO-NCCN-NICE).